Approval · Notice of Compliance 12 · 2004
BRIMONIDINE: Notice of Compliance 12
Issued March 9, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12
- Date
- March 9, 2004
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- Relatively selective alpha2-adrenoceptor agonist, elevated intraocular pressure therapy
- Canadian reference product
- ALPHAGAN (Allergan Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BRIMONIDINE | 02249456 | Cancelled Pre Market |
Medicinal ingredients
- BRIMONIDINE TARTRATE 0.2 PER